Simple Summary Cardiovascular diseases (CVDs) are the leading causes of death
worldwide. Epicardial adipose tissue (EAT) is one of the most important risk factors for …

(1) Sodium–glucose cotransporter-2 inhibitors (SGLT2-i) reduce adipose tissue and
cardiovascular events in patients with type 2 diabetes (T2D). Accumulation of epicardial …

Obesity is associated with higher risks of cardiac arrhythmias. Although this may be partly
explained by concurrent cardiometabolic ill-health, growing evidence suggests that …

Epicardial adipose tissue (EAT) and pericardial adipose tissue (PAT) are metabolically
active fat depots implicated in cardiovascular disease, and EAT has potential as a novel …

Morphological characteristics and source of adipose tissue as well as adipokines may
increase cardiometabolic risk. This study aimed to explore whether adipose tissue …

Background Epicardial adipose tissue (EAT) accumulation is associated with multiple
cardiometabolic risk factors and prognosis of heart failure with preserved ejection fraction …

A sedentary lifestyle is associated with overweight/obesity, which involves excessive fat
body accumulation, triggering structural and functional changes in tissues, organs, and body …

Background and aims Glucagon-like peptide-1 (GLP-1) analogues reduce body fat and
cardiovascular events in patients with type 2 diabetes. Accumulation of epicardial adipose …

Background and aims This study investigates the expression of novel adipocytokines and
inflammatory cells infiltration in epicardial adipose tissue (EAT) and subcutaneous adipose …

A large body of evidence arising from recent randomized clinical trials demonstrate the
association of vascular inflammatory mediators with coronary artery disease (CAD) …